These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31587427)

  • 1. Low-dose anti-hepatitis B immunoglobulin regimen as prophylaxis for hepatitis B recurrence after liver transplantation.
    Lee WC; Chou HS; Wu TH; Cheng CH; Lee CF; Wang YC; Wu TJ; Chan KM
    Transpl Infect Dis; 2019 Dec; 21(6):e13190. PubMed ID: 31587427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral Combination Therapy With Low-Dose Hepatitis B Immunoglobulin for the Prevention of Hepatitis B Virus Recurrence in Liver Transplant Recipients: A Single-Center Experience.
    Akcam AT; Ulku A; Rencuzogullari A; Eray IC; Okoh A; Kuran S; Dalcı K; Yalav O; Parsak CK; Sakman G; Demiryurek H
    Transplant Proc; 2015 Jun; 47(5):1445-9. PubMed ID: 26093739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
    Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
    Darweesh SK; Gad AA; Akroof K; ElLatif ZA
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
    Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
    Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.
    Rosenau J; Kreutz T; Kujawa M; Bahr MJ; Rifai K; Hooman N; Finger A; Michel G; Nashan B; Kuse ER; Klempnauer J; Tillmann HL; Manns MP
    J Hepatol; 2007 Apr; 46(4):635-44. PubMed ID: 17316869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
    Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation.
    Ku W; Wang U; Nguyen MH
    Expert Opin Biol Ther; 2015 May; 15(5):665-77. PubMed ID: 25865452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation.
    Jiang L; Yan L; Wen T; Li B; Zhao J; Yang J; Xu M; Wang W
    Transplant Proc; 2013; 45(6):2326-30. PubMed ID: 23953544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving experience of hepatitis B virus prophylaxis in liver transplantation.
    Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO
    Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
    Stärkel P; Stoffel M; Lerut J; Horsmans Y
    Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Newer Nucleos(t)ide Analogs After Hepatitis B Immunoglobulin Discontinuation Against Hepatitis B and D Recurrence in Liver Transplant Recipients.
    Cholongitas E; Oikonomou T; Bafa K; Sinakos E; Papatheodoridis GV; Goulis I
    Transplantation; 2024 Sep; 108(9):e239-e244. PubMed ID: 38557857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis.
    Beckebaum S; Herzer K; Bauhofer A; Gelson W; De Simone P; de Man R; Engelmann C; Müllhaupt B; Vionnet J; Salizzoni M; Volpes R; Ercolani G; De Carlis L; Angeli P; Burra P; Dufour JF; Rossi M; Cillo U; Neumann U; Fischer L; Niemann G; Toti L; Tisone G
    Ann Transplant; 2018 Nov; 23():789-801. PubMed ID: 30420590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.